CANAKINUMAB and RASH

Overview

RASH is the #10 most commonly reported adverse reaction for CANAKINUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 558 FDA adverse event reports linking CANAKINUMAB to RASH. This represents approximately 2.2% of all 25,877 adverse event reports for this drug.

Patients taking CANAKINUMAB who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

RASH is a less commonly reported adverse event for CANAKINUMAB, but still significant enough to appear in the safety profile.

Other Side Effects of CANAKINUMAB

In addition to rash, the following adverse reactions have been reported for CANAKINUMAB:

• PYREXIA — 1,405 reports
• INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION — 1,242 reports
• DRUG INEFFECTIVE — 1,189 reports
• INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION — 953 reports
• PAIN — 934 reports
• CONDITION AGGRAVATED — 841 reports
• MALAISE — 714 reports
• OFF LABEL USE — 679 reports
• ARTHRALGIA — 605 reports
• INCORRECT DOSE ADMINISTERED — 502 reports

Other Drugs Associated with RASH

The following drugs have also been linked to rash in FDA adverse event reports:

Does CANAKINUMAB cause RASH?

RASH has been reported as an adverse event in 558 FDA reports for CANAKINUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is RASH with CANAKINUMAB?

RASH accounts for approximately 2.2% of all adverse event reports for CANAKINUMAB, making it a notable side effect.

What should I do if I experience RASH while taking CANAKINUMAB?

If you experience rash while taking CANAKINUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages